The University of Kansas Cancer Center

Fairway, Kansas 66205

5 studies enrolling now · 14 studies all time

What they study most

Advanced Breast Cancer, Advanced Solid Tumors With KRAS G12C Mutations, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Aggressive B-Cell Non-Hodgkin Lymphoma, B Cell Lymphoma, Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, DLBCL, DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation, DLBCL - Diffuse Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma

Studies at this site

• A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer — Recruiting now
• AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) — Recruiting now
• Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined — Recruiting now
• SynKIR-310 for Relapsed/Refractory B-NHL — Recruiting now
• A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors — Recruiting now
• Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis — Running, not enrolling
• Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) — Running, not enrolling
• Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant — Stopped early
• Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS — Stopped early
• A Study of TAS-120 in Patients With Advanced Solid Tumors — Completed
• Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma — Completed
• A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) — Running, not enrolling
• Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma — Completed
• CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) — Completed